Refine
Has Fulltext
- yes (102)
Is part of the Bibliography
- yes (102)
Year of publication
Document Type
- Journal article (102) (remove)
Language
- English (102) (remove)
Keywords
- therapeutic drug monitoring (4)
- chemistry (3)
- human (3)
- pharmacokinetics (3)
- polyphenols (3)
- population pharmacokinetics (3)
- positron emission tomography (3)
- synthesis (3)
- ARONJ (2)
- Alzheimer’s disease (2)
- Chemie (2)
- Ernährung (2)
- Medizin (2)
- S-ADAPT (2)
- allometric scaling (2)
- azobenzenes (2)
- body composition (2)
- body size (2)
- butyrylcholinesterase (2)
- capillary electrophoresis (2)
- crystal structure (2)
- cystic fibrosis patients (2)
- cytochrome P450 3A4 (CYP3A4) (2)
- dendritic cells (2)
- drug design (2)
- drugs (2)
- drug–drug interactions (DDIs) (2)
- estrogens (2)
- gene expression (2)
- graft versus host disease (2)
- healthy volunteers (2)
- human breast (2)
- kinetics (2)
- leishmaniasis (2)
- medicine (2)
- multiple linear regression (2)
- natural products (2)
- norepinephrine transporter (2)
- nutrition (2)
- octopamine (2)
- osteoarthritis (2)
- osteonecrosis of the jaw (2)
- osteoradionecrosis (2)
- physiologically based pharmacokinetic (PBPK) modeling (2)
- protein binding (2)
- solubility (2)
- strategy (2)
- structure-activity relationships (2)
- sympathetic nervous system (2)
- therapy (2)
- thermogenesis (2)
- 1 (1)
- 2,5-diketopiperazines (1)
- 2-Thiazaphospholidines (1)
- 2-chloro (1)
- 2-halo (1)
- 2-imino- (1)
- 3 (1)
- 77-LH-28-1 (1)
- AAA+ ATPase p97 (1)
- AChE inhibitor (1)
- AD mouse modele (1)
- ADAMTS (1)
- AGP (1)
- Akt/PKB (1)
- Alzheimer's diseas (1)
- Alzheimer's disease (1)
- Alzheimer′s disease (1)
- Analytical Quality by Design (1)
- Asymmetrie (1)
- Aziridines (1)
- BRAF mutation (1)
- Benzimidazole (1)
- CAD detection (1)
- CO‐releasing molecules (CORMs) (1)
- CYP2C9 (1)
- CYP3A4 (1)
- Cabozantinib (1)
- Candida albicans (1)
- Candida auris (1)
- Cecropia telenitida (1)
- Charged aerosol detector (CAD) (1)
- Citrus (1)
- Commercial preparations (1)
- Contaminants (1)
- Cutaneous leishmaniasis (1)
- Enterobacteriaceae (1)
- Eriodictyon californicum (1)
- Escherichia coli (1)
- FV45 (1)
- Fatty acids (1)
- Flavonoids (1)
- G-protein coupled receptor (1)
- GABA (1)
- GABAB receptor agonists (1)
- GABA\(_{A}\) receptor (1)
- GABA\(_{B}\) (1)
- Geschichte (1)
- Gradient boosted trees (GBT) (1)
- HNSCC (1)
- HPLC–MS (1)
- High-performance liquid chromatography (HPLC) (1)
- Hydrogen-deuterium (1)
- IR (1)
- Ibuprofen (1)
- Imidates (1)
- Imidoyl halides (1)
- Impact-Faktor (1)
- In vivo studies (1)
- Klebsiella pneumoniae (1)
- Kohlenhydrate (1)
- LC-ESI/MS/MS (1)
- LC-MS/MS (1)
- LpxC inhibitors (1)
- MRONJ (1)
- MYCNv (1)
- Manganese Carbonyl ligands (1)
- Melatonin (1)
- Microglia (1)
- Mitsunobu (1)
- Natural product hybrids (1)
- ONJ (1)
- Osmunda regalis (1)
- PET (1)
- Paeonia (1)
- Phenolic acids (1)
- Positronen-Emissions-Tomografie (1)
- Pycnogenol (1)
- Quantitative structure-property relationship modeling (QSPR) (1)
- RESP model (1)
- Red Sea (1)
- Robuvit\(^®\) (1)
- Ruxolitinib (1)
- SPECT (1)
- Schistosomiasis (1)
- Spectrofluorimetry (1)
- Staphylococcus aureus (1)
- Streptomyces axinellae (1)
- Synthesis (1)
- T cell (1)
- T-shaped π-π stacking (1)
- T-shaped π–π stacking (1)
- TDDFT (1)
- Tanzania (1)
- Tryptophan (1)
- V. wallichii (1)
- Valeriana wallichii (1)
- Wissenschaftliches Arbeiten (1)
- Xanomeline (1)
- \(^{1}\)HNMR (1)
- absolute bioavailability (1)
- acebutolol (1)
- acetic acid (1)
- acetones (1)
- acetonitrile (1)
- acetylcholinesterase (1)
- acid value (1)
- acids (1)
- activation (1)
- additive manufacturing (1)
- afatinib (1)
- affinity (1)
- agar diffusion test (1)
- alignment (1)
- allergic rhinitis (1)
- allosteric modulation (1)
- amber codon suppression (1)
- amber light (1)
- ampicillin (1)
- amyloid beta (1)
- amyloid-β (Aβ) (1)
- angiotensin II type 1 receptor (1)
- anti-inflammatory activity (1)
- anti-proliferative effects (1)
- anti-schistosomal activity (1)
- anti-trypanosomal (1)
- antibacterial activity (1)
- antibacterials (1)
- antibiotic bone concentration (1)
- antifungal drug (1)
- antileishmanial (1)
- antimicrobial resistance (1)
- antimicrobial stewardship (1)
- antiresorptive drug-related osteonecrosis of the jaw (1)
- antiviral agents (1)
- at-home sampling (1)
- autoinjector (1)
- autophagy (1)
- baclofen (1)
- baclofen homologues (1)
- beta-lactam (1)
- beta-lactam antibiotics (1)
- bile (1)
- bile salt (1)
- binding analysis (1)
- bio-orthogonal chemistry (1)
- bioactivity (1)
- biochemical simulations (1)
- biocide polyhexamethylene biguanide (1)
- biodiversity (1)
- bioisosterism (1)
- biophysics (1)
- biosensor (1)
- biosynthesis (1)
- bitopic hybrid ligands (1)
- bitopic ligand (1)
- blood brain barrier (1)
- blood plasma (1)
- boat conformation (1)
- bone marrow (1)
- bronchial tissue (1)
- brucei (1)
- caffeic acid bornyl ester (1)
- carbamate (1)
- cardiac innervation imaging (1)
- cardiac neurohormonal system (1)
- cartilage (1)
- cecropia telenitida (1)
- cefotiam (1)
- cell metabolism (1)
- cells (1)
- cerebEND cells (1)
- charged aerosol detector (1)
- chemotherapy (1)
- chenopodium quinoa (1)
- chiral (1)
- chiral resolution (1)
- chiral separation (1)
- cholinergic system (1)
- cholinesterases inhibitors (1)
- circular dichroism (1)
- citrus (1)
- click chemistry (1)
- clinical study (1)
- cofactors (biochemistry) (1)
- cold stress (1)
- colloid (1)
- commercial preparations (1)
- complementary medicine (1)
- computational chemistry (1)
- contaminants (1)
- crithidia fasciulata (1)
- cyclodextrins (1)
- cysteine protease (1)
- cytokine modulation (1)
- cytokine production (1)
- cytotoxicity (1)
- dabrafenib (1)
- decafluoroazobezene (1)
- dehydration (1)
- derivates (1)
- design of experiments (1)
- detector (1)
- diabetes (1)
- diketopiperazines (1)
- discovery (1)
- dissolution (1)
- dissolution rates (1)
- drug impurities (1)
- drug metabolism (1)
- drug monitoring (1)
- drug-delivery systems (1)
- electroactive (1)
- electrohydrodynamic (1)
- emulsions oil-in-water (1)
- enantiomers (1)
- endothelium (1)
- enoyl-ACP reductase inhibitors (1)
- enterohepatic recirculation (1)
- enzyme kinetics (1)
- enzymes (1)
- ephedrine (1)
- epitope mapping (1)
- ester value (1)
- ethanol (1)
- ethers (1)
- eugenyl cinnamate (1)
- exchange reaction (1)
- excipient (1)
- experimental visceral leishmaniasis (1)
- extraction (1)
- fatty acids (1)
- fenoterol (1)
- field testing (1)
- flavonoid (1)
- flavonoids (1)
- fluorescence resonance energy transfer (1)
- fluorescent ligands (1)
- fluorescent probes (1)
- fluorine-18 (1)
- fluoroquinolone (1)
- fluticasone propionate (1)
- flux (1)
- forms (1)
- fragment screening (1)
- fragment-based design (1)
- gallotannins (1)
- gastrointestinal (1)
- genetics (1)
- gentamicin sulfate (1)
- glucos metabolism (1)
- glucose (1)
- glutathione (1)
- glycocalyx (1)
- glycolytic flux control (1)
- gradient HPLC–UV (1)
- gut microbiota; bioactivation; polyphenols; complex carbohydrates; tryptophan (1)
- hMSC-TERT (1)
- head and neck carcinoma (1)
- heart failure (1)
- high performance liquid chromatography (1)
- high-resolution tandem mass spectrometry (1)
- high-throughput screening (1)
- histamine (1)
- history (1)
- homodimerization (1)
- homology modeling (1)
- honeybee (1)
- honeybees (1)
- human receptor kinetics (1)
- hybrid molecules (1)
- hydnocarpin (1)
- hydrogels (1)
- hydrogen bonding (1)
- hydrogen bonding mycobacterium tuberculosis (1)
- hydrolysis (1)
- hydroxy-dabrafenib (1)
- hypoxia (1)
- hysterectomy (1)
- imaging (1)
- impurity profiling (1)
- in vitro (1)
- in vitro dissolution methods (1)
- in vitro dissolution testing (1)
- in vitro-in vivo correlation (1)
- in vivo dissolution (1)
- information technology (1)
- internal transcribed spacer 2 (1)
- intramolecular Michael addition (1)
- intranasal corticosteroids (1)
- intrinsic metabolism (1)
- invasion (1)
- iodine value (1)
- ipratropium bromide (1)
- isolation (1)
- isomerization (1)
- isosteviol sodium (1)
- jaw bone (1)
- kappa-B activation (1)
- ketamine (1)
- kinase inhibitors (1)
- leaves (1)
- linear discriminant analysis (1)
- liquid chromatography electrospray ionization tandem mass spectrometry (1)
- liquid chromatography tandem mass spectrometry (LC-MS/MS (1)
- liquid chromatography-mass spectrometry (1)
- liver impairment (1)
- maceration (1)
- macrophages (1)
- magnesium stearate (1)
- manufacturer (1)
- marine metagenomics (1)
- marine natural products (1)
- marine organisms (1)
- marine sponge (1)
- maritime pine bark extract (1)
- matrix metalloproteinases (1)
- medicine authentication tools (1)
- melanoma (1)
- melatonin (1)
- metabolic glycoengineering (1)
- metabolic network model (1)
- metabolism (1)
- metastasis (1)
- micelles (1)
- microscopy (1)
- mobile apps (1)
- modified monosaccharides (1)
- molecular mechanics (1)
- molecular systematics (1)
- multicomponent Ugi-type reaction (1)
- muscarinic M1 receptor (1)
- muscarinic acetylcholine receptors (1)
- muscarinic receptors (1)
- natural product (1)
- natural product hybrids (1)
- nerve agent (1)
- neuroblastoma cell (1)
- neuroprotection (1)
- neuroprotectivity (1)
- nicotinic receptors (1)
- nitric oxide (1)
- non-racemic (1)
- nonhuman primates (1)
- novel nepetolactone derivative (1)
- nuclear cardiology (1)
- oak wood (1)
- oak wood extract (1)
- obtusifolia bertol (1)
- octopamine receptors (1)
- oleanane saponins (1)
- online monitoring system (1)
- opioid ligands (1)
- opioid receptors (1)
- oral anticancer drugs (1)
- oral bioavailability (1)
- oral drug absorption (1)
- oral microbiome (1)
- osimertinib (1)
- oxidative stress (1)
- oxime (1)
- oxygen (1)
- oxytosis/ferroptosis (1)
- parasite (1)
- paromomycin (1)
- patch clamp recording (1)
- pefloxacin (1)
- pentacyclic triterpene (1)
- peptide sensors (1)
- peptide stapling (1)
- perfluoroarylation (1)
- peri-implant disease (1)
- personalized antimicrobial therapy (1)
- pharmaceutical analysis (1)
- pharmacological evaluation (1)
- phosphoglycolate phosphatase (1)
- photocontrol (1)
- photopharmacology (1)
- phylogenetic tree (1)
- phylogeny (1)
- phytochemicals (1)
- pine bark extract (1)
- piperacillin/tazobactam (1)
- plant extract (1)
- plants (1)
- plasma proteins (1)
- podophyllotoxin (1)
- polymer drug interaction (1)
- polymer processing (1)
- polymers (1)
- polysorbate 80 (1)
- posaconazole (1)
- post-operative recovery (1)
- post-surgery recovery (1)
- pressurized microwave‐assisted extraction (1)
- principal component analysis (1)
- proliferation (1)
- propionate (1)
- protease inhibition (1)
- protease inhibitors (1)
- proteasome system (1)
- protein engineering (1)
- psidium guajava; (1)
- pulmonary absorption (1)
- purification (1)
- pyridobenzodiazepine (1)
- qPCR (1)
- quality evaluation (1)
- quantitative 1H NMR (1)
- quantum mechanics (1)
- radiotracer (1)
- radiotracer kinetics (1)
- radiotracers (1)
- randomized controlled study (1)
- rat study (1)
- red blood cells (1)
- red fruit oil (1)
- renal cell carcinoma (1)
- renin-angiotensin system (1)
- replica-exchange molecular dynamics (1)
- required hydrophilic–lipophilic balance (1)
- resistance (1)
- response surface (1)
- ribosomal RNA (1)
- ruxolitinib (1)
- sacha inchi oil (1)
- saponification Value (1)
- saturation transfer difference NMR (1)
- schistosoma (1)
- schistosomula (1)
- screening (1)
- secondary structure (1)
- secretion (1)
- sensory chewing gums (1)
- serjanic acid (1)
- serum (1)
- short-range order (1)
- silybin (1)
- simulated intestinal fluid (1)
- single-molecule microscopy (1)
- sisomicin (1)
- solid-state NMR spectroscopy (1)
- spectrofluorimetry (1)
- spray (1)
- staphylococcus aureus (1)
- sterubin (1)
- streptomyces (1)
- structural elucidation (1)
- structure-activity relationship (1)
- structure–activity relationships (1)
- substandard and falsified medicines (1)
- synovial fluid (1)
- system (1)
- tacrine (1)
- tetromycin (1)
- thin-layer chromatography (1)
- thymyl cinnamate (1)
- tongue (1)
- topical treatment (1)
- toxicity (1)
- track and trace (1)
- trametinib (1)
- transport (1)
- triacylglycerides (1)
- trypanosoma cruzi (1)
- type 2 diabetes (1)
- ultrafiltration (1)
- unnatural amino acid (1)
- unsaturated fatty acids (1)
- urolithins (1)
- ursolic acid (1)
- vacuoles (1)
- validation (1)
- valsartan (1)
- valtrates (1)
- veterinarians (1)
- veterinary medicine (1)
- volumetric absorptive micro-sampling (VAMS) (1)
- volumetric absorptive microsampling (1)
Institute
- Institut für Pharmazie und Lebensmittelchemie (102) (remove)
Sonstige beteiligte Institutionen
- Apotheke, Universitätsklinikum Würzburg (1)
- Helmholtz Institute for RNA-based Infection Biology (HIRI), Josef-Schneider-Straße 2/D15, DE-9708 Wuerzburg, Germany (1)
- Helmholtz Institute for RNA-based Infection Biology (HIRI), Josef-Schneider-Straße 2/D15, DE-97080 Wuerzburg, Germany (1)
- Johns Hopkins School of Medicine (1)
- Krankenhaushygiene und Antimicrobial Stewardship, Universitätsklinikum Würzburg (1)
- Max Planck Institute for Biophysical Chemistry, Am Faßberg 11, DE-37077 Goetingen, Germany (1)
- Novartis Pharma AG, Lichtstrasse 35, CH-4056 Basel, Switzerland (1)
- Zentraleinheit Klinische Massenspektrometrie (1)
- Zentrallabor, Universitätsklinikum Würzburg (1)
EU-Project number / Contract (GA) number
- 26230120009 (1)
- 296679 (1)
- 314911 (1)
- 701983 (1)
A liquid chromatography tandem mass spectrometry method for the analysis of ten kinase inhibitors (afatinib, axitinib, bosutinib,cabozantinib, dabrafenib, lenvatinib, nilotinib, osimertinib, ruxolitinib, and trametinib) in human serum and plasma for theapplication in daily clinical routine has been developed and validated according to the US Food and Drug Administration andEuropean Medicines Agency validation guidelines for bioanalytical methods. After protein precipitation of plasma samples withacetonitrile, chromatographic separation was performed at ambient temperature using a Waters XBridge® Phenyl 3.5μm(2.1×50 mm) column. The mobile phases consisted of water-methanol (9:1, v/v) with 10 mM ammonium bicarbonate as phase A andmethanol-water (9:1, v/v) with 10 mM ammonium bicarbonate as phase B. Gradient elution was applied at a flow rate of 400μL/min. Analytes were detected and quantified using multiple reaction monitoring in electrospray ionization positive mode. Stableisotopically labeled compounds of each kinase inhibitor were used as internal standards. The acquisition time was 7.0 min perrun. All analytes and internal standards eluted within 3.0 min. The calibration curves were linear over the range of 2–500 ng/mLfor afatinib, axitinib, bosutinib, lenvatinib, ruxolitinib, and trametinib, and 6–1500 ng/mL for cabozantinib, dabrafenib, nilotinib,and osimertinib (coefficients of correlation≥0.99). Validation assays for accuracy and precision, matrix effect, recovery,carryover, and stability were appropriate according to regulatory agencies. The rapid and sensitive assay ensures high throughputand was successfully applied to monitor concentrations of kinase inhibitors in patients.
Metabolic glycoengineering enables a directed modification of cell surfaces by introducing target molecules to surface proteins displaying new features. Biochemical pathways involving glycans differ in dependence on the cell type; therefore, this technique should be tailored for the best results. We characterized metabolic glycoengineering in telomerase-immortalized human mesenchymal stromal cells (hMSC-TERT) as a model for primary hMSC, to investigate its applicability in TERT-modified cell lines. The metabolic incorporation of N-azidoacetylmannosamine (Ac\(_4\)ManNAz) and N-alkyneacetylmannosamine (Ac\(_4\)ManNAl) into the glycocalyx as a first step in the glycoengineering process revealed no adverse effects on cell viability or gene expression, and the in vitro multipotency (osteogenic and adipogenic differentiation potential) was maintained under these adapted culture conditions. In the second step, glycoengineered cells were modified with fluorescent dyes using Cu-mediated click chemistry. In these analyses, the two mannose derivatives showed superior incorporation efficiencies compared to glucose and galactose isomers. In time-dependent experiments, the incorporation of Ac\(_4\)ManNAz was detectable for up to six days while Ac\(_4\)ManNAl-derived metabolites were absent after two days. Taken together, these findings demonstrate the successful metabolic glycoengineering of immortalized hMSC resulting in transient cell surface modifications, and thus present a useful model to address different scientific questions regarding glycosylation processes in skeletal precursors.
Baclofen (1) is a potent and selective agonist for bicuculline-insensitive GABAB receptors and is used clinically as an antispastic and muscle relaxant agent. In the search for new bioactive chemical entities that bind specifically to GABAB receptors, we report here the synthesis of certain baclofen homologues, namely (R,S)-5-amino-3-arylpentanoic acid hydrochlorides (R,S)-1a–h as well as (R,S)-5-amino-3-methylpentanoic acid [(RS)-1i] to be evaluated as GABABR agonists. Compound 1a is an agonist to GABAB receptors with an EC50 value of 46 μM on tsA201 cells transfected with GABAB1b/GABAB2/Gqz5, being the most active congener among all the synthesized compounds.
Cholinesterases are important biological targets responsible for regulation of cholinergic transmission, and their inhibitors are used for the treatment of Alzheimer’s disease. To design new cholinesterase inhibitors, of different structure-based design strategies was followed, including the modification of compounds from a previously developed library and a fragment-based design approach. This led to the selection of heterodimeric structures as potential inhibitors. Synthesis and biological evaluation of selected candidates confirmed that the designed compounds were acetylcholinesterase inhibitors with \(IC_{50}\) values in the mid-nanomolar to low micromolar range, and some of them were also butyrylcholinesterase inhibitors.
Most drugs are no longer produced in their own countries by the pharmaceutical companies, but by contract manufacturers or at manufacturing sites in countries that can produce more cheaply. This not only makes it difficult to trace them back but also leaves room for criminal organizations to fake them unnoticed. For these reasons, it is becoming increasingly difficult to determine the exact origin of drugs. The goal of this work was to investigate how exactly this is possible by using different spectroscopic methods like nuclear magnetic resonance and near- and mid-infrared spectroscopy in combination with multivariate data analysis. As an example, 56 out of 64 different paracetamol preparations, collected from 19 countries around the world, were chosen to investigate whether it is possible to determine the pharmaceutical company, manufacturing site, or country of origin. By means of suitable pre-processing of the spectra and the different information contained in each method, principal component analysis was able to evaluate manufacturing relationships between individual companies and to differentiate between production sites or formulations. Linear discriminant analysis showed different results depending on the spectral method and purpose. For all spectroscopic methods, it was found that the classification of the preparations to their manufacturer achieves better results than the classification to their pharmaceutical company. The best results were obtained with nuclear magnetic resonance and near-infrared data, with 94.6%/99.6% and 98.7/100% of the spectra of the preparations correctly assigned to their pharmaceutical company or manufacturer.
Biosensor techniques have become increasingly important for fragment-based drug discovery during the last years. The AAA+ ATPase p97 is an essential protein with key roles in protein homeostasis and a possible target for cancer chemotherapy. Currently available p97 inhibitors address its ATPase activity and globally impair p97-mediated processes. In contrast, inhibition of cofactor binding to the N-domain by a protein-protein-interaction inhibitor would enable the selective targeting of specific p97 functions. Here, we describe a biolayer interferometry-based fragment screen targeting the N-domain of p97 and demonstrate that a region known as SHP-motif binding site can be targeted with small molecules. Guided by molecular dynamics simulations, the binding sites of selected screening hits were postulated and experimentally validated using protein- and ligand-based NMR techniques, as well as X-ray crystallography, ultimately resulting in the first structure of a small molecule in complex with the N-domain of p97. The identified fragments provide insights into how this region could be targeted and present first chemical starting points for the development of a protein-protein interaction inhibitor preventing the binding of selected cofactors to p97.
Quinolone antibiotics present an attractive oral treatment option in patients with cystic fibrosis (CF). Prior studies have reported comparable clearances and volumes of distribution in patients with CF and healthy volunteers for primarily renally cleared quinolones. We aimed to provide the first pharmacokinetic comparison for pefloxacin as a predominantly nonrenally cleared quinolone and its two metabolites between both subject groups. Eight patients with CF (fat-free mass [FFM]: 36.3 ± 6.9 kg, average ± SD) and ten healthy volunteers (FFM: 51.7 ± 9.9 kg) received 400 mg pefloxacin as a 30 min intravenous infusion and orally in a randomized, two-way crossover study. All plasma and urine data were simultaneously modelled. Bioavailability was complete in both subject groups. Pefloxacin excretion into urine was approximately 74% higher in patients with CF compared to that in healthy volunteers, whereas the urinary excretion of metabolites was only slightly higher in patients with CF. After accounting for body size and composition via allometric scaling by FFM, pharmacokinetic parameter estimates in patients with CF divided by those in healthy volunteers were 0.912 for total clearance, 0.861 for nonrenal clearance, 1.53 for renal clearance, and 0.916 for volume of distribution. Nonrenal clearance accounted for approximately 90% of total pefloxacin clearance. Overall, bioavailability and disposition were comparable between both subject groups.
Amber Light Control of Peptide Secondary Structure by a Perfluoroaromatic Azobenzene Photoswitch
(2023)
The incorporation of photoswitches into the molecular structure of peptides and proteins enables their dynamic photocontrol in complex biological systems. Here, a perfluorinated azobenzene derivative triggered by amber light was site‐specifically conjugated to cysteines in a helical peptide by perfluoroarylation chemistry. In response to the photoisomerization (trans→cis) of the conjugated azobenzene with amber light, the secondary structure of the peptide was modulated from a disorganized into an amphiphilic helical structure.
Renin–angiotensin system (RAS) plays an important role in the regulation of blood pressure and hormonal balance. Using positron emission tomography (PET) technology, it is possible to monitor the physiological and pathological distribution of angiotensin II type 1 receptors (AT\(_1\)), which reflects the functionality of RAS. A new \(^{18}\)F-labeled PET tracer derived from the clinically used AT\(_1\) antagonist valsartan showing the least possible chemical alteration from the valsartan structure has been designed and synthesized with several strategies, which can be applied for the syntheses of further derivatives. Radioligand binding study showed that the cold reference FV45 (K\(_i\) 14.6 nM) has almost equivalent binding affinity as its lead valsartan (K\(_i\) 11.8 nM) and angiotensin II (K\(_i\) 1.7 nM). Successful radiolabeling of FV45 in a one-pot radiofluorination followed by the deprotection procedure with 21.8 ± 8.5% radiochemical yield and >99% radiochemical purity (n = 5) enabled a distribution study in rats and opened a path to straightforward large-scale production. A fast and clear kidney uptake could be observed, and this renal uptake could be selectively blocked by pretreatment with AT\(_1\)-selective antagonist valsartan. Overall, as the first \(^{18}\)F-labeled PET tracer based on a derivation from clinically used drug valsartan with almost identical chemical structure, [\(^{18}\)F]FV45 will be a new tool for assessing the RAS function by visualizing AT\(_i\) receptor distributions and providing further information regarding cardiovascular system malfunction as well as possible applications in inflammation research and cancer diagnosis.
Heart failure is one of the growing causes of death especially in developed countries due to longer life expectancy. Although many pharmacological and instrumental therapeutic approaches have been introduced for prevention and treatment of heart failure, there are still limitations and challenges. Nuclear cardiology has experienced rapid growth in the last few decades, in particular the application of single photon emission computed tomography (SPECT) and positron emission tomography (PET), which allow non-invasive functional assessment of cardiac condition including neurohormonal systems involved in heart failure; its application has dramatically improved the capacity for fundamental research and clinical diagnosis. In this article, we review the current status of applying radionuclide technology in non-invasive imaging of neurohormonal system in the heart, especially focusing on the tracers that are currently available. A short discussion about disadvantages and perspectives is also included.